Parathyroid adenomas are benign tumors in the parathyroid glands, whose pathogenesis is largely unknown. We utilized an expression cDNA cloning strategy to identify oncogenes activated in parathyroid adenomas. An expression cDNA library was prepared directly from a clinical sample of parathyroid adenoma tissue, transfected into NIH3T3 cells, and foci of morphologically transformed cells were isolated. Following plasmid rescue, we identi®ed cDNAs for the keratinocyte growth factor receptor at a high frequency. Interestingly, approximately half of the clones encoded a variant receptor containing an altered C-terminus. Analysis of the transforming activity of the variant receptor revealed that the altered C-terminus upregulated the transforming activity in a ligand-independent manner. The higher transforming activity was not accompanied by increase of dimerization or overall autophosphorylation of the receptor. However, tyrosine phosphorylation of downstream receptor substrates, including Shc isoforms and possibly FRS2, are increased in the transfectants expressing the parathyroid tumorderived receptor. Genomic analysis showed that a previously unidenti®ed exon was used to form the novel isoform. This alternative splicing appears to occur preferentially in parathyroid adenomas.
Introduction
The prevalence of primary hyperparathyroidism is estimated to be 1/500 ± 1/1000. In 80 ± 85% of the cases, the disease is caused by a benign, solitary adenoma (Bilezikian, 1993) . The pathogenesis of this disease is largely unknown. In a small fraction of parathyroid adenomas (*5%), a rearrangement of chromosome 11 has been reported (Arnold et al., 1989) . In this case, the PRAD1 gene, which encodes a cell cycle regulator cyclin D1, is fused with the 5' regulatory region of the parathyroid hormone gene by a pericentromeric inversion of chromosome 11.
However, the molecular basis for the development of the large majority of parathyroid adenomas has yet to be clari®ed.
A standard method to isolate transforming genes activated in tumors involves focus formation assays in NIH3T3 mouse ®broblasts upon transfection of genomic DNA isolated from tumors. However, this approach contains multiple, labor intensive steps including cloning and structural analysis of integrated genomic sequences. Due to the diculty of extraction and ineciency of transfection of large genomic DNA, certain transforming genes may escape detection in these assays. Additionally, promoters of certain oncogenes may not be active in recipient NIH3T3 cells. To circumvent such problems, we have developed an ecient expression cDNA cloning system (Miki et al., 1991b) and isolated transforming cDNAs from established cell lines (Miki et al., 1991a Chan et al., 1994) . However, a more straightforward approach to clone oncogenes would be to perform expression cloning using cDNA libraries prepared directly from tumor tissue RNAs.
Here, we adopted this approach to the identi®cation of transforming cDNAs directly from clinically isolated parathyroid adenoma tissue and isolated a novel variant form of keratinocyte growth factor receptor (KGFR) with increased transforming activity. This receptor contains an altered C-terminal domain that was generated by alternative splicing. Analysis of this and other variant receptors indicated that at least four isoforms with dierent C-terminal domains are generated by alternative splicing, and activated at dierent levels.
Results

Expression cloning of transforming cDNAs from a parathyroid adenoma
An expression cDNA library of 2610 7 individual plaques was constructed in lpCEV29 from 5 mg of poly (A) + RNA extracted from a parathyroid adenoma, designated PA-1. A part of the library (5610 6 plaques) was ampli®ed and used to transfect NIH3T3 cells. Foci of transformed cells were identi®ed and isolated over 10 ± 18 days after transfection. Following G-418 selection and expansion to mass cultures, genomic DNA was prepared and subjected to plasmid rescue as described (Miki et al., 1991b) . From 12 foci induced by the PA-1 cDNA library, plasmids with high-titered transforming activity were rescued. Sequence analysis of the 5'-portion of the cDNAs revealed that one cDNA encodes platelet-derived growth factor B chain (PDGF-B/c-sis), while the other 11 clones contained 5'-untranslated sequence of the FGFR2/BEK gene.
The FGFR2/BEK gene encodes two growth factor receptors with distinct ligand binding speci®cities (Miki et al., 1992) . These two receptors, ®broblast growth factor receptor 2 (FGFR2) and keratinocyte growth factor receptor (KGFR), dier only 49 amino acids in the second half of the immunoglobulin-like domain 3 (Ig3), which is encoded by an alternative exon (see Figure 2 ). FGFR2 binds aFGF and bFGF, while KGFR binds aFGF and KGF. KGF (also known as FGF-7) is a pracrine mediator of epithelial cell growth (Finch et al., 1989) . Murine and human KGF equally elicit responses in epithelial cell types of human or mouse origin. When introduced into NIH3T3 cells, KGFR, but not FGFR2, induces foci of morphologically transformed cells, because NIH3T3 ®broblasts secrete KGF which can bind to and activate KGFR. We used a PCR approach to identify the receptor type as previously reported (Miki et al., 1991a) and found that all of the 11 cDNAs encode a KGFR type receptor (data not shown).
The FGFR2 gene is not ampli®ed in parathyroid adenomas
The FGFR2 gene is known to be ampli®ed in stomach cancer cell lines (Hattori et al., 1990) . To test whether the gene has been ampli®ed in the parathyroid Figure 1 Analysis of KGFR isolated from PA-1 parathyroid adenoma. (a) Southern blotting of DNAs from PA-1 parathyroid adenoma (T) and normal placenta (N). Genomic DNA was digested with BamHI or EcoRI, fractionated on a 0.8% agarose gel and stained with ethidium bromide (left panel). Following electrophoresis, gels were blotted onto a nylon membrane and hybridized with 32 P-labeled probes derived from 5' half or 3' half of the full-length KGFR cDNA cleaved at the EcoRI site in the tyrosine kinase 2 domain (center and right panels). (b) PCR ampli®cation of the tyrosine kinase 2 and C-terminal domains of KGFR clones isolated from the PA-1 cDNA library. PCR products were fractionated by a 1% agarose gel electrophoresis and stained by ethidium bromide. Lanes a and b represent the samples produced using a common forward primer TM160 (located at 5' side of TK2) and a reverse primer, TM188 (located at 3' side of TK2) or TM189 (located at 3' side of the C-terminus), respectively, in the presence of cloned cDNA as template. Lane c represents the sample produced using TM160 and TM188 in the absence of template DNA. (c) Nucleotide sequence of the novel C-terminal variant of KGFR. The predicted amino acid sequence starts at the residue 765 of the wild-type KGFR. Italicized letters indicate the amino acid and nucleotide sequences distinct from the wild-type KGFR adenoma, we analysed PA-1 genomic DNA by Southern blotting analysis using a KGFR cDNA as probe. As shown in Figure 1a , neither the pattern nor the intensity of restriction fragments of PA-1 DNA was dierent from that of human placental DNA, indicating that there is no major alteration or ampli®cation of the FGFR2 gene in the PA-1 adenoma DNA. We also isolated genomic DNAs from four other dierent parathyroid adenoma tissues and peripheral blood of the same patients, and compared the gene dose in these normal and tumor DNAs by a similar analysis. No signi®cant ampli®cation of the FGFR2 gene or alteration of the band pattern was detected in these tumor samples (data not shown), suggesting that FGFR2 ampli®cation is not a frequent event in parathyroid adenomas. Overexpression of KGFR may be responsible for the frequent detection of KGFR as transforming cDNA clones. However, we could not address this possibility due to the limited availability of the tumor tissues. Another possibility for the frequent detection of KGFR in this assay is that KGFR is activated in this parathyroid adenoma. Receptor-type tyrosine kinases are frequently activated in various tumors by replacement of the ligand-binding domains with other gene products through chromosomal rearrangement (Sawyers and Denny, 1994) . To test whether the ligand-binding domains of these receptor clones are intact, we used restriction analysis and DNA sequencing. No evidence for such structural alterations was obtained.
KGFR-PA contains an altered C-terminus
We have previously found that alterations of the Cterminus of KGFR/FGFR2 can stimulate the receptor's transforming activity (Lorenzi et al., 1996) . Therefore, we examined a possibility that PA-1 parathyroid adenoma might express KGFR with a similar C-terminal variation. Eleven KGFR cDNA clones rescued from the NIH3T3 transformants were subjected to PCR analysis using primer pairs that can amplify the tyrosine kinase domain 2 (TK2), and the region encompassing TK2 and Cterminal domains (TK2/C), respectively. While the TK2 domain was ampli®ed from all of the clones (Figure 1b) , the TK2/C region was not ampli®ed from six clones, suggesting that these clones do not contain the wild-type C-terminus. Furthermore, restriction enzyme digestion and PCR analysis Figure 2 Transforming activity of C-terminal variants of FGFR2/KGFR. Schematic representation of various FGFR2/KGFR isoforms with C-terminal domain variation are shown. The location of signal peptide (S), acidic (A), immunoglobulin-like (Ig2 and Ig3), transmembrane TM, juxtamembrane (JM), tyrosine kinase (TK1 and TK2), kinase insert (KI), and C-terminal (C) domains are shown above the scheme. The isoforms used in this study do not contain the Ig3 domain. KGFR-type isoforms contain the sequence encoded by the K exon of the FGFR2 gene in the second half of Ig3 domain (shaded area). Transforming activity of each variant is shown at the right as focus forming unit (u)/pmol DNA. The experiment was repeated three times and a typical result was shown. Two constructs of FGFR2-PA, which were derived from independent KGFR-PA isolates, showed similar transforming activity Figure 3 Dimerization of FGFR2 C-terminal variants. NIH3T3 cells expressing various receptors or the vector alone were incubated in the presence (+) or absence (7) of disuccinimidyl suberate for 20 min at 48C, lysed, and immunoprecipitated by an anti-FGFR2 antibody. The immunoprecipitated samples were separated by SDS ± PAGE with a 6% resolving gel and blotted with the anti-FGFR2 antibody (aFGFR2) showed that three of the 11 clones contained two Ig loops and others were three-Ig-loop forms, which was later con®rmed by DNA sequencing. All of these clones contained the KGFR-speci®c K exon sequence (Miki et al., 1992) in the Ig3 domain, and the three 2-loop KGFR clones also contained the acidic box. DNA sequence of the C-terminal region of all these clones revealed that the six clones, from which TK2/ C was not ampli®ed, indeed had a dierent Cterminus, and that the sequences diverged from the wild-type receptor at the amino acid 770 (Figure 1c ). These KGFR variants from the parathyroid adenoma were designated KGFR-PA.
Altered C-terminus of KGFR-PA activates transforming activity
Since KGFR-PA is structurally altered, we reasoned that its activity is upregulated. Examination of transforming activity revealed that KGFR variants with the altered C-terminus induced focus formation in NIH3T3 cells at a higher eciency than the normal counterpart ( Figure 2 ). The C-terminal variants with 2 Ig loops and those with 3 Ig loops were equally active (data not shown). However, the transforming activity of KGFR variants were dicult to compare in accuracy, because normal KGFR also showed a strong transforming activity due to stimulation of the receptor by KGF secreted from NIH3T3 cells. To circumvent this problem, we converted these KGFR variants with altered C-terminus and the wild-type KGFR (KGFR-WT) to the FGFR2 isoforms that cannot be activated by KGF-binding. Chimeric molecules were generated that have the extracellular domain of wild-type 2-loop FGFR2 (FGFR2-WT) and the cytoplasmic domain of KGFR-PA or KGFR-WT. As shown in Figure 2 , FGFR2-WT did not exhibit any detectable transforming activity, whereas two FGFR2-PA constructs derived from independently isolated KGFR-PA clones showed high activity. These results indicate that the altered C-terminus of KGFR-PA results in activation of the receptor without ligand binding. Another C-terminal variant of KGFR, KGFR-ET (early termination) (Lorenzi et al., 1996) , also showed relatively high transforming activity, when its FGFR2-form, FGFR2-ET, was used to compare the activity with FGFR2-WT (Figure 2 ).
High focus forming activity of FGFR2-PA is not accompanied by increase of receptor dimerization or autophosphorylation
We have previously reported a transforming isoform of FGFR2 generated by chromosomal rearrangement with a novel gene, FRAG1, at the C-terminus of the receptor (Lorenzi et al., 1996) . The FGFR2-FRAG1 recombinant protein showed increased transforming activity due, in part, to the constitutive dimerization of the receptor. To examine if the mechanism might account for the increased transforming activity of the FGFR2-PA, NIH3T3 transfectants expressing various FGFR2/KGFR isoforms were treated with or without a cross-linking reagent, disuccinimidyl suberate, and the lysate was analysed by immunoblotting for the receptor after immunoprecipitation and SDS ± PAGE. As shown in Figure 3 , FGFR2-WT, FGFR2-ET or KGFR showed a high molecular weight band of 4200 kD when the cross-linker was present. The dimerization of FGFR2-WT in the stable transfectants without ligand binding might be caused by crowding the receptor molecules in the membrane by its overexpression. Since two individually constructed FGFR2-PAs were expressed at lower levels, the ratio of monomers and dimers were estimated by scanning the autoradiogram. No signi®cant dierences of dimer/ monomer ratio was found between FGFR2-PAs and Figure 4 Tyrosine phosphorylation of the KGFR/FGFR2 variants. NIH3T3 cells were transfected with the expression vector alone (pCEV29) or the vector containing various KGFR/FGFR2 cDNA constructs. The receptor species were immunoprecipitated from the same amount of cell lysates by the anti-FGFR2 antibody (aFGFR2). The immunoprecipitated samples were fractionated by SDS ± PAGE with a 7.5% resolving gel, transferred onto a membrane, and blotted by an anti-phosphotyrosine antibody (aPTYR) (left panel) or aFGFR2 (right panel) FGFR2-WT transfectants. Therefore, constitutive dimerization might not play a major role on activation of FGFR2-PA.
To examine the eect of C-terminal domain of FGFR2-PA on the phosphorylation state of the receptor, we immunoprecipitated the receptors from the lysates of transfectants with an anti-FGFR2 antibody and analysed the phosphorylation levels of the receptors by Western blotting with an antiphosphotyrosine antibody. As shown in Figure 4 , left panel, the wild-type receptor showed a low level of phosphorylation, and the KGFR isoform, which could be stimulated by secreted KGF, was highly phosphorylated. In contrast, two individually constructed FGFR2-PA clones (FGFR2-PA1 and PA2) and FGFR2-ET displayed almost undetectable levels of receptor phosphorylation. Reprobing the same membrane with an anti-FGFR2 antibody revealed similar expression levels of the various constructs in these transfectants (Figure 4, right panel) . We recently found that FGFR2 isoforms containing two Ig domains and an acidic domain are extensively modi®ed by glycosaminoglycans (Sakaguchi et al., manuscript submitted). The diuse, high molecular weight bands of FGFR2 variants in Figure 5 bottom panel represent glycosaminoglycan-modi®ed forms.
Substrate phosphorylation is increased in FGFR-PA transfectants
Although we did not detect overall increase of autophosphorylation of FGFR2-PA, autophosphorylation might occur at speci®c sites to upregulate the kinase activity of the receptor. To test this possibility, we examined the phosphorylation levels of FGFR substrates. Tyrosine phosphorylated proteins were immunoprecipitated from the transfectants expressing FGFR2 isoforms by an antiphosphotyrosine antibody and detected by the same antibody. As shown in Figure 5 , transfectants expressing two independently isolated FGFR2-PA clones exhibited increased tyrosine phosphorylated proteins, suggesting that kinase activity of FGFR2-PAs is upregulated. The phosphorylation levels in these transfectants were higher than FGFR-ET transfectants and closer to KGFR transfectants, which were stimulated by secreted KGF. One of the phosphorylated proteins increased in FGFR2-PA transfectants as well as FGFR2-ET and KGFR transfectants migrated as a doublet of 92 ± 95 kD. These characteristics are similar to those of FGF Receptor Substrate 2 (FRS2), a lipid-anchored Grb2-binding protein (Kouhara et al., 1997) . Other phosphoproteins of 68, 52 and 46 kD were characteristic to known Shc isoforms and detected by anti-Shc antibodies (middle panel). In these transfectants, the expression levels of the receptor isoforms were comparable, although they showed dierent patterns due to the glycosaminoglycan modi®cations (bottom panel). All of these results indicate that the kinase activity of FGFR2-PA is upregulated in a ligandindependent manner.
KGFR-PA is generated by alternative splicing
Analysis of the nucleotide sequence of the altered Cterminus of KGFR-PA revealed that it was derived from the 3'-untranslated region of KGFR-WT transcript. Comparison of nucleotide sequences of KGFR-PA and KGFR-WT cDNAs revealed that a simple deletion of 352 bp from the normal receptor cDNA could create a receptor with the altered C-terminus. Three alternative exons encoding the C-terminus of FGFR2/KGFR have been reported (Itoh et al., 1994) . Nucleotide sequence of the C-terminus of KGFR-PA is dierent from those of the known three alternative exons. Therefore, the fourth exon encoding the Cterminus of KGFR-PA was designated C4, which could be localized in a 3'-portion of the exon encoding the normal C-terminus, C1 (Figure 6a) . To examine the exact location of exon C4, we performed a PCR Figure 5 Tyrosine phosphorylation of downstream signaling molecules. NIH3T3 cells transfected with the expression vector alone (pCEV29) or the vectors carrying various KGFR/FGFR2 variants were immunoprecipitated from the same amount of cell lysates by an anti-phosphotyrosine antibody (aPY) (top and middle panels) or anti-FGFR2 antibody (aFGFR2) (bottom panel). The immunoprecipitated samples were fractionated by SDS ± PAGE with a 7.5% resolving gel, transferred onto a membrane, and immunoblotted by an anti-phosphotyrosine antibody (top panel), anti-Shc antibody (aSHC) (middle panel) or aFGFR2 (bottom panel) analysis of genomic DNA using a forward primer, 1, located in the exon for TK2 domain, and reverse primers, 2 and 4, located in exons C1 and C4, respectively ( Figure 6a ). As shown in Figure 6b , these pairs of primers ampli®ed fragments expected by the location of the exons. The similar sizes of the PCR products by the primer pairs 1, 2 and 1, 4 suggested that no intron is located between exons C1 and C4. This result was further con®rmed by the PCR experiments using primers 3 and 4, located in the exons C1 and C4 respectively. Essentially the same results were obtained by using genomic DNA from the placenta and the parathyroid adenoma (PA-1) as PCR templates.
To examine if the variant form of KGFR was derived from mutations in the intron/exon boundaries of an allele of the FGFR2 gene, the region encoding the C-terminus was ampli®ed by PCR from the tumor and placenta genomic DNA separately, and subcloned into the pCRII vector. Sequencing of seven separate DNA subclones from the tumor revealed no mutations or deletions present in this region as compared to those of the placenta. These ®ndings excluded the possibility of allelic dierence at this region, and con®rmed the previous observation that the formation of KGFR-PA was not due to a deletion in the FGFR2 gene in the parathyroid adenoma. It is likely that KGFR-PA represents a novel isoform which contains an altered C-terminus generated by alternative splicing. Taken together with the known C-terminal variations, our results indicate that the exons for C2, C1 and C4 are overlapped (Figure 6a ). In contrast, the C3 domain is encoded by a separate exon which contains a polyadenylation signal and therefore does not overlap other exons (Itoh et al., 1994) . As shown in Figure 6c , all four variants encode dierent C-terminal sequences.
KGFR-PA is preferentially expressed in parathyroid adenomas
We examined the expression of KGFRs with four dierent C-termini in normal parathyroid glands, adenomas, hyperplastic parathyroid glands due to renal failure, a parathyroid cancer, and several nonparathyroid tumors. Three C-terminal variants (C1, C2 and C4) can be ampli®ed as products with distinct sizes by RT ± PCR using primers 1 and 4 (see Figure 6a) . As shown in Figure 7 , RT ± PCR analysis showed that the C1 (WT) and C2 (ET) variants were detected in all the tissues and cells except the cell line from a colon cancer (20471/2022), where only the weak expression of C1 was detected. Interestingly, the C4 variant was present in all ®ve parathyroid adenomas (PA-1 *5) and one of two hyperplastic parathyroid glands (HP-1), while the normal parathyroid glands (PT) and one parathyroid cancer (PT-CA) did not detectably express this Cterminal variant. Among the several tumor-derived cell lines tested, expression of C4 was detected in three of the four gastric cancer cell lines (SNU16, KATO-III and SNU1). Since the FGFR2 gene has been ampli®ed (Hattori et al., 1990) , detection of C4 in these cell lines may not re¯ect the relative abundance of the variant. Analysis of the C3 variant (K-SAM-IIC3 type) revealed its expression in three of ®ve adenomas (PA-1, PA-4 and PA-5), one of two hyperplastic parathyroid glands (HP-1), but not in the normal parathyroid glands or a parathyroid cancer. All four cell lines derived from gastric cancer (SNU16, KATO-III, SNU1 and N87) also expressed this C3 variant, although the expression in SNU1 is relatively weak. These expression studies suggest that, although the C1 and C2 splice variants are prevalent in all the tissues or cells, the C4 variant is a unique splice variant preferentially expressed in parathyroid adenomas. In contrast, the C3 variant seems to be more common in gastric cancers. Interestingly, an immortalized cell line derived from normal skin epithelial cells (B5/589) expressed all four C-terminal variants.
Discussion
We have used an expression cloning strategy to isolate transforming cDNAs directly from a parathyroid adenoma. Parathyroid adenomas are relatively small tumors. Although tumor tissues are of limited availability in quantity, successful isolation of transforming cDNA clones from a small tumor tissue indicates that this expression cloning strategy is highly feasible to identify oncogenes activated in other tumor tissues where tissue specimens are limiting.
Among the KGFR clones isolated from the parathyroid adenoma, we have identi®ed a novel Cterminal splice variant, KGFR-PA. Together with other known variants, K-SAM-IIC3 (Itoh et al., 1994) and KGFR-ET (Lorenzi et al., 1996) , our ®ndings suggest that four KGFR isoforms with dierent C-termini are generated by alternative splicing (Figure 6a ). The C-terminal domain of K-SAM-IIC3 is encoded by the C3 exon, which contains a translation termination codon and polyadenylation sequence (Itoh et al., 1994) . In contrast, the C-terminal domains of other variants are encoded by overlapping exons, C2, C1 and C4. The C2 exon contains two other alternative splice acceptor sites. Use of the second and third splice acceptors selects the C1 and C4 exons, respectively, and generates receptor variants with dierent C-terminal domains. Since the translated regions in these three overlapping exons are not identical, these variants contain dierent C-terminal amino acid sequences. Interestingly, the N-terminal half sequence of the C1 domain is closely related to the C2 domain, while the C4 domain has no signi®cant similarity to other C-terminal domains (Figure 6c) .
Identi®cation of KGFR-PA as a C-terminal splice variant of KGFR suggested that the C-terminus of KGFR is an important determinant of the receptor function. The transforming potency of the C-terminal variants of KGFR was dicult to assess in NIH3T3 cells, since the cells are transformed by the formation of an autocrine loop between ectopically expressed KGFR and endogenously expressed, secreted KGF. Therefore, the eect of variant C-terminus on transforming activity was estimated after replacing the ectodomain of KGFR with that of FGFR2. The C-terminal variants with FGFR2 ectodomain, FGFR2-PA and FGFR2-ET, had potent transforming activity, while the wild-type FGFR2 showed no such activity. Although the transforming activity of another Cterminal variant of KGFR, K-SAM-IIC3, was reported to be higher than KGFR (Itoh et al., 1994) , the transforming activity of FGFR2 form of K-SAM-IIC3 has not been examined. Because KGFR isoforms can be stimulated by KGF secreted from the cells, the transforming activity of K-SAM-IIC3 without KGF stimulation is still unknown.
The immunoblotting studies using an anti-phosphotyrosine antibody showed that overall tyrosine phosphorylation level of FGFR2-PA was quite low. The C-terminal domain of FGFR2-WT contains ®ve tyrosines and some of them may be major phosphorylation sites. In contrast, FGFR2-PA does not contain any tyrosine residues in its C-terminal domain ( Figure  6c ). One of the major phosphorylation sites is tyrosine Figure 7 Expression of KGFR/FGFR2 C-terminal variants in normal and tumor cells. RT ± PCR was used to detect dierent Cterminal domains. For detecting C1, C2 and C4, a pair of primers, 1 and 4 (see Figure 6a) were used, while for C3, the primers described previously (Itoh et al., 1994) were used. PT, parathyroid; PA, parathyroid adenoma; HP, hyperplastic parathyroid caused by renal failure; CA, parathyroid cancer. HCT116 and 20471/2022, cell lines derived from colon cancers; SNU16, KATOIII, SNU1 and N87, cell lines derived from gastric cancers; HA83, a cell line derived from glioblastoma; MCF7, a cell line derived from a breast cancer; B5/589, a cell line derived from skin epithelial cells. The sizes of PCR bands, C1, C2, C3 and C4, were 455, 547, 299 and 104 base pairs, respectively 770 (see Figure 6c) , which is also required for the association with and activation of phospholipase Cg by FGFRs (Mohammadi et al., 1992; Peters et al., 1992) . Lack of this site may be a reason why overall autophosphorylation of KGFR-PA is relatively low. It is possible that increased phosphorylation of speci®c sites in these receptor isoforms upregulates their transforming activity despite the low levels of overall autophosphorylation. The phosphorylation levels of FGFR2 substrates were markedly increased in FGFR2-PA transfectants as compared with the wildtype receptor transfectants (Figure 5) , indicating that the kinase activity of FGFR2-PA is actually increased.
Activated forms of receptor-type tyrosine kinases have been identi®ed in various tumor cells, where their ligand-binding domains have been replaced by other gene products. In addition to the removal of the negative regulatory, ligand-binding domains, the newly acquired sequences can stimulate dimerization of the receptor variants (Sawyers and Denny, 1994) . In contrast to these activated receptors, FGFR2-PA did not show signi®cant increase of dimerization without ligand stimulation, suggesting that constitutive dimerization is not a major cause of the higher transforming activity of FGFR2-PA. Since the C-terminal sequence of FGFR2-PA has no similarity with known sequences, the function of C4 domain is dicult to assess. The C4 domain of FGFR2-PA may relieve to some extent the negative regulation of receptor activity by its ligandbinding domain. Alternatively, the C4 domain may stimulate the receptor activity through binding to a factor, which inhibits the receptor activation.
KGFR-PA was preferentially expressed in parathyroid adenomas and in a fraction of the parathyroid hyperplasia due to renal failure. This variant was not detectably expressed in normal parathyroid tissue. Since tumors develop from normal cells by stepwise alterations of several protooncogenes and tumor suppressors, constitutively active variant forms of KGFR, such as KGFR-PA, might be involved in tumor development by stimulating the cell growth. It will be of interest to examine if KGFR-PA is a tumoramplifying factor of the parathyroid adenoma especially in the steps where its ligands are not available for receptor activation.
Materials and methods
Expression cloning and functional analysis of KGFR-PA
Expression cloning was performed as described (Miki et al., 1991b; Miki and Aaronson, 1993) using an improved expression vector lpCEV29 (Lorenzi et al., 1999) . Chimeras consisting of the ectodomain of FGFR2-WT and the intracellular domain of the KGFR from parathyroid adenoma were constructed in the expression vector pCEV29 (Lorenzi et al., 1999) . Brie¯y, a BglII ± AscI fragment of FGFR2-WT was replaced by the corresponding fragment from KGFR-PA cDNA to generate FGFR2-PA. The FGFR2-PA1 and FGFR2-PA2 cDNAs were derived from independently isolated two KGFR-PA clones. The FGFR2-WT was previously constructed as a chimera consisting of the ectodomain of FGFR2 and the intracellular domain of the wild-type KGFR and represents a wild-type FGFR2 containing two Ig loops and an acidic domain (Lorenzi et al., 1996) . KGFR and FGFR2-ET have been described elsewhere (Miki et al., 1991a; Lorenzi et al., 1997) . Focus formation assays were performed as described (Miki and Aaronson, 1995) .
PCR analysis of KGFR isoforms
PCR ampli®cation of the KGFR C-terminal domain using genomic DNA as template was carried out in the following conditions: 25 cycles of 948C for 1 min, 608C for 2 min and 728C for 3 min. Primers used were forward primers (F) designated 1 and 3, and reverse primers (R) designated 2 and 4 with the following sequences:
1. 5'-TTGGTAGAAGACTTGGATCGAAT-3' 2. 5'-GAATACTGTTCGAGAGGTTGGC-3' 3. 5'-AGTAATCAGCATATGTGTAAAGA-3' 4. 5'-TGAGAGGGGTTACATGGTGGCTTG-3'.
The locations of these primers in the KGFR/FGFR2 cDNA are shown in Figure 5a .
PCR ampli®cation of the KGFR tyrosine kinase 2 and Cterminal domains using cDNA clones as template was performed using the same conditions. A forward primer, TM160, and two reverse primers, TM188 for the tyrosine kinase 2 domain and TM189 for the C-terminal domain, were used for the reactions. The primers had following sequences: TM160: 5'-GCAGACTTTGGACTCGCCAG-3' TM188: 5'-CCAACAGTCCCTCATCATG-3' TM189: 5'-GCCGTTTATGTGTGGATACTG-3'
RNA analysis
RT ± PCR was carried out using 0.05 mg of poly(A) + RNA or 0.5 mg of total RNA as template. After reverse transcription of RNA with random hexamers as primer, PCR reactions were performed as follows: 35 cycles of 1 min at 958C, 1 min at 608C and 2 min at 728C. The following primers were used: for detection of C1, C2 and C4, a forward primer, 5'-TTGGTAGAAGACTTGGATCGAAT-3' and a reverse primer 5'-TGAGAGGGGTTACATGGTGGCTTG-3'; for detection of C3, a forward primer, 5'-AGAGTATACACT-CATCAGAGTGATGTC-3', and a reverse primer, 5'-GTTTCTCAATGAAGCCATAAACTTTCAGAT-3'. PCR products were fractionated by a 3.5% Metaphore gel electrophoresis, and visualized by ethidium bromide staining.
